Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANPCNASDAQ:BIOCNASDAQ:MGENNASDAQ:OPGNNASDAQ:PMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANPCFresh2 Group$4.37$4.92$2.60▼$11.99$4.24M1.5526,396 shs35,704 shsBIOCBiocept$0.97$0.32▼$27.00$1.14M0.69764,067 shs751,400 shsMGENMiragen Therapeutics$15.67+2.9%$17.69$4.66▼$34.05$61.24M1.66134,027 shs396,663 shsOPGNOpGen$4.73$4.83$0.53▼$5.25$47.62M-1.689,280 shs88 shsPMDPsychemedics$2.67$2.52$1.50▼$3.25N/AN/A35,163 shs113,627 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANPCFresh2 Group0.00%0.00%0.00%0.00%0.00%BIOCBiocept0.00%0.00%0.00%0.00%0.00%MGENMiragen Therapeutics0.00%+9.35%+10.74%+30.69%+28.87%OPGNOpGen0.00%+0.64%+5.11%+18.25%+80.53%PMDPsychemedics0.00%0.00%0.00%0.00%+14.59%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANPCFresh2 GroupN/AN/AN/AN/AN/AN/AN/AN/ABIOCBioceptN/AN/AN/AN/AN/AN/AN/AN/AMGENMiragen TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOPGNOpGenN/AN/AN/AN/AN/AN/AN/AN/APMDPsychemedicsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANPCFresh2 Group 0.00N/AN/AN/ABIOCBiocept 0.00N/AN/AN/AMGENMiragen Therapeutics 0.00N/AN/AN/AOPGNOpGen 0.00N/AN/AN/APMDPsychemedics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANPCFresh2 Group$1.75M2.42N/AN/A($1.41) per share-3.10BIOCBiocept$25.86M0.00N/AN/A$15.60 per share0.00MGENMiragen Therapeutics$4.46M13.73N/AN/A$6.78 per share2.31OPGNOpGen$2.67M17.82N/AN/A($11.55) per share-0.41PMDPsychemedics$19.68M0.83N/AN/A$0.84 per share3.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANPCFresh2 Group-$14.77MN/A0.00∞N/AN/AN/AN/AN/ABIOCBiocept-$32.09M-$58.45N/AN/AN/AN/A-468.87%-118.41%N/AMGENMiragen Therapeutics-$41.87M-$20.09N/AN/AN/A-1,393.50%-141.66%-88.74%N/AOPGNOpGen-$32.67MN/A0.00∞N/A-1,140.36%N/A-287.58%7/7/2025 (Estimated)PMDPsychemedics-$1.86M-$0.510.00∞N/A-9.26%-32.32%-18.53%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANPCFresh2 GroupN/AN/AN/AN/AN/ABIOCBioceptN/AN/AN/AN/AN/AMGENMiragen TherapeuticsN/AN/AN/AN/AN/AOPGNOpGenN/AN/AN/AN/AN/APMDPsychemedicsN/AN/AN/AN/A1 YearsCompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANPCFresh2 GroupN/A0.320.32BIOCBiocept2.881.811.70MGENMiragen Therapeutics0.204.234.23OPGNOpGenN/A5.455.45PMDPsychemedics0.011.821.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANPCFresh2 Group45.84%BIOCBioceptN/AMGENMiragen TherapeuticsN/AOPGNOpGen2.68%PMDPsychemedics32.07%Insider OwnershipCompanyInsider OwnershipANPCFresh2 Group26.22%BIOCBiocept1.61%MGENMiragen Therapeutics1.10%OPGNOpGen43.80%PMDPsychemedics13.96%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANPCFresh2 Group86970,000715,000Not OptionableBIOCBiocept502.63 million2.58 millionNot OptionableMGENMiragen Therapeutics453.91 millionN/ANot OptionableOPGNOpGen10010.07 million4.70 millionNot OptionablePMDPsychemedics1406.11 million5.26 millionNot OptionableMGEN, BIOC, ANPC, OPGN, and PMD HeadlinesRecent News About These CompaniesPsychemedics Releases 2025 Workforce Insights ReportJune 16, 2025 | globenewswire.comPsychemedics Named “Most Innovative Drug Testing Company of the Year”May 16, 2025 | globenewswire.comPsychemedics Launches Groundbreaking Quartile Reporting for Enhanced Drug Testing InsightsMarch 3, 2025 | markets.businessinsider.comPhoenix Molecular Designs Launches Phase II Trial in RSK2-High Breast CancerFebruary 21, 2025 | precisionmedicineonline.comPInsider Buying: Psychemedics Co. (NASDAQ:PMD) Major Shareholder Acquires 60,000 Shares of StockDecember 18, 2024 | insidertrades.comPsychemedics Co. (NASDAQ:PMD) Major Shareholder Purchases $19,355.07 in StockDecember 13, 2024 | insidertrades.comInsider Buying: Psychemedics Co. (NASDAQ:PMD) Director Purchases 1,409,712 Shares of StockDecember 6, 2024 | insidertrades.comPsychemedics announces reverse stock split, forward stock splitDecember 3, 2024 | markets.businessinsider.comPsychemedics Corporation Announces Reverse and Forward Stock SplitDecember 2, 2024 | gurufocus.comPsychemedics Corporation Announces 1-for-5,000 Reverse Stock Split Followed by 5,000-for-1 Forward Stock SplitDecember 2, 2024 | quiverquant.comQPsychemedics Corporation Announces Reverse and Forward Stock SplitDecember 2, 2024 | globenewswire.comPsychemedics reminds stockholders to cast votes for Annual MeetingNovember 19, 2024 | markets.businessinsider.comPsychemedics Corporation Reminds Stockholders to Cast Their Votes for Upcoming Annual Meeting of StockholdersNovember 18, 2024 | markets.businessinsider.comPsychemedics Reports Improved Losses Amid Revenue DipNovember 15, 2024 | markets.businessinsider.comPsychemedics Corporation Reports Third Quarter 2024 Financial ResultsNovember 12, 2024 | globenewswire.comPsychemedics Corporation (PMD)October 15, 2024 | finance.yahoo.comPsychemedics Releases First-Ever Education Insights Report: Uncovering Drug Trends in Educational Institutions Through Hair TestingSeptember 26, 2024 | globenewswire.comPsychemedics Corporation Launches New Ketamine Hair Testing ServiceAugust 29, 2024 | finance.yahoo.comPsychemedics Corporation Reports Second Quarter 2024 Financial ResultsAugust 13, 2024 | globenewswire.comPsychemedics Corporation’s Board of Directors Approves Plan to Terminate Registration of Its ...August 12, 2024 | bakersfield.comBMedia Sentiment Over TimeMGEN, BIOC, ANPC, OPGN, and PMD Company DescriptionsFresh2 Group NASDAQ:ANPCAnPac Bio-Medical Science Co., Ltd., a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. It also offers physical checkup package services. The company was incorporated in 2010 and is headquartered in Lishui, the People's Republic of China.Biocept NASDAQ:BIOCBiocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. On October 13, 2023, Biocept, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.Miragen Therapeutics NASDAQ:MGENMiragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.OpGen NASDAQ:OPGN$4.73 0.00 (0.00%) As of 07/3/2025OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.Psychemedics NASDAQ:PMDPsychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol. The company's testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. It offers its services to employers for job applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. The company was incorporated in 1986 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
